Merck Accelerates Drug-Submission Plans
Mid-Year Applications Are Goal for Keytruda for Lung Cancer, New Hep C Treatment
By Peter Loftus
The Wall Street Journal
Jan. 11, 2015 11:04 p.m. ET
Merck & Co. has accelerated its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in a bid to close the gap with competitors in two lucrative segments...
Merck also plans to file an application in the first half of this year for FDA approval to market a new two-drug, single-pill combination to treat the liver disease hepatitis C. The drugs, grazoprevir and elbasvir, cured at least 90% of infected patients in a mid-stage clinical trial and Merck is testing them in late-stage studies.
The company previously said it expected to file for regulatory approval of the hepatitis C regimen sometime during 2015...
Continue reading....
No comments:
Post a Comment